CAMBRIDGE, Mass., Feb. 4, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins, Infinity Pharmaceutical's Chief Executive Officer, will present at the BIO CEO & Investor Conference on Monday, February 11, 2019, at 10:00 a.m. EST at The New York Marriott Marquis in New York, NY. A live webcast of the presentation will be available on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event.
About Infinity
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. MARIO-1, a Phase 1/1b study in approximately 200 patients with advanced solid tumors is ongoing, and Infinity plans to initiate MARIO-275, a global, randomized study evaluating the addition of IPI-549 to nivolumab in cisplatin-refractory, I/O naïve urothelial cancer patients, in the first half of 2019. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Contact:
Stephanie Ascher, Stern Investor Relations, Inc.
212-362-1200 or Stephanie@sternir.com
SOURCE Infinity Pharmaceuticals, Inc.
